Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
Open randomized therapeutic study to assess the efficacy of Xarelto 15mg/day in the
recurrence of thromboembolic event compared to an untreated group in patients with chronic
portal vein thrombosis without high risk thrombophilia.